U.S. Communications Stock News

WTW stock moves after forecast cut and new data center risk product Willis Towers Watson (WTW) has been in focus after a broker reduced earnings forecasts, citing higher corporate expenses and possible AI pressure on consulting, even as the firm rolled out a new data center risk solution. See our latest analysis for Willis Towers Watson. At a share price of US$296.56, WTW has seen a 2.99% 7 day share price return but a 9.11% year to date share price decline, while the 5 year total shareholder...

Context for Piper Sandler Companies (PIPR) Piper Sandler Companies (PIPR) has drawn investor attention after recent share price moves, with the stock showing a 24.9% gain over the past month but a slight decline over the past 3 months. See our latest analysis for Piper Sandler Companies. Recent trading has been strong, with a 6.6% 7 day share price return and a 23.9% 30 day share price return, set against a more moderate 4.2% year to date share price return and a 71.9% 1 year total...

Pentagon officials have held recent high level meetings with GE Aerospace (NYSE:GE) and major U.S. automakers to discuss increasing domestic weapons production. The discussions focus on using commercial manufacturing expertise to expand output of drones and missiles to address inventory shortfalls. This initiative aims to broaden the U.S. defense industrial base by involving civilian manufacturers in defense supply chains. For GE Aerospace, the talks highlight how its existing role as a key...

In April 2026, Beach House Behavioral Health, a portfolio company of BelHealth Investment Partners, announced a new partnership with Centene’s Ambetter Health, expanding access to behavioral health services for patients in recovery. This collaboration highlights Centene’s continuing emphasis on its core government-sponsored and managed care offerings, reinforcing its focus on coordinated, accessible healthcare coverage. Next, we’ll examine how heightened hedge fund interest and this Ambetter...

Waters Corporation recently launched the omniDAWN Multi-Angle Light Scattering Photometer, an extended-range MALS detector for UHPLC and UPLC workflows, and supported FDA-cleared at-home use of the Onclarity HPV Self-Collection Kit in collaboration with BD, expanding its role in advanced analytical and diagnostic solutions. By combining higher-throughput, lower-consumption biopharma analytics with at-home HPV screening infrastructure, Waters is reinforcing its position at the intersection of...

Palo Alto Networks (PANW) is back in focus after NWN expanded its partnership to combine Prisma Access monitoring with NWN’s Experience Management Platform, targeting secure access and visibility for state, local, education and broader public sector clients. See our latest analysis for Palo Alto Networks. The NWN partnership headlines come as the share price trades at US$169.56, with recent momentum improving, including a 7 day share price return of 4.34%. The 1 year total shareholder return...

Without a single clear event driving headlines, Ardagh Metal Packaging (AMBP) has still drawn attention as investors weigh its recent share performance against fundamentals like revenue of US$5,497m and a reported net loss of US$11m. See our latest analysis for Ardagh Metal Packaging. At a share price of US$4.11, Ardagh Metal Packaging’s near term moves have been mixed, with a 4.85% 1 month share price return contrasting with a much stronger 71.10% 1 year total shareholder return. This...

Sandisk stock overview after recent performance Sandisk (SNDK) has drawn fresh attention after a strong run over the past month and past 3 months, with recent returns contrasting with a small pullback in the latest trading day. See our latest analysis for Sandisk. At a share price of $913.02, Sandisk has seen short-term momentum cool after sharp gains, with a 7-day share price return of a 4.14% decline alongside a 30-day share price return of 28.65% and a year-to-date share price return of...

Legend Biotech (NasdaqGS:LEGN) is back in focus after reporting 2025 results that spotlight its multiple myeloma therapy CARVYKTI, now used in more than 10,000 patients, alongside a major US manufacturing expansion. See our latest analysis for Legend Biotech. The recent 41.7% 7 day and 44.0% 30 day share price returns suggest momentum has picked up around CARVYKTI milestones and the manufacturing expansion, although the 1 year total shareholder return of 22.2% decline highlights that longer...

How the Padres sale is feeding interest in Atlanta Braves Holdings The record US$3.9b sale of the San Diego Padres has sharpened attention on the value of elite baseball franchises, and Atlanta Braves Holdings (BATR.K) is trading in that spotlight after a 5% gain on heavy volume. See our latest analysis for Atlanta Braves Holdings. The Padres deal comes on top of a strong run in Atlanta Braves Holdings' shares, with a 30 day share price return of 17.91% and a 1 year total shareholder return...

In recent days, Atlassian Corporation Plc was removed from the NASDAQ-100 Index, even as it rolled out new AI-powered Confluence features like Remix and partner agents for Lovable, Replit, and Gamma. By turning Confluence into an AI-driven content engine that links directly into third-party prototype, coding, and presentation tools, Atlassian is aiming to deepen its role in how teams create and reuse work across different platforms. We’ll now examine how Atlassian’s new AI-driven Confluence...

Wondering whether CVR Energy at around US$30.18 still offers value, or if the easy gains are behind it? This article walks through what the recent performance and current pricing might be telling you. The stock has seen a 3.6% decline over the last 7 days and a 10.8% decline over the last 30 days, even though the year to date return is 19.8% and the 1 year return sits at 65.4%. Those moves come after a multi year run in which the 3 year return is 30.9% and the 5 year return is 211.0%. These...

Wondering whether Check Point Software Technologies at around US$138 still lines up with what you think it is worth? This article walks through what the current price might be implying about the stock's value. The share price has recently closed at US$138.15, with returns of a 2.8% decline over 7 days, 9.5% decline over 30 days, 23.7% decline year to date, and 33.4% decline over the last year, compared to gains of 5.5% over 3 years and 17.7% over 5 years. These moves have arrived alongside...

Wondering whether MP Materials at US$66.23 is priced for perfection or still offers value? This article breaks down what the current share price might be implying about the stock. The stock has posted returns of 16.6% over 7 days, 30.9% over 30 days, 20.5% year to date, 185.6% over 1 year and 191.2% over 3 years, with a 5 year return of 107.0%. Recent market attention on MP Materials has focused on its role in the rare earths supply chain and its exposure to long term demand for materials...

Event Context and Recent Share Performance Chart Industries (GTLS) has drawn investor interest after relatively steady recent share performance. The stock has returned about 0.1% over the past week, 0.5% over the past month, and 0.4% over the past 3 months. See our latest analysis for Chart Industries. While the 1-day share price return of 0.08% decline and recent short term moves have been muted, the 1-year total shareholder return of 75.31% points to strong longer term momentum around...

Investors may be wondering whether Arthur J. Gallagher at around US$223 a share still stacks up as a fair deal, or if the price now reflects too much optimism or caution. The stock has been relatively steady over the last week at 0.3% and is up 3.8% over the last month. However, that sits against a 12.9% year-to-date decline and a 29.5% slide over the last year, which may change how you think about both risk and potential upside. Recent headlines around Arthur J. Gallagher have focused on...

On March 28, 2026, Arcutis Biotherapeutics presented new Phase 2 INTEGUMENT-INFANT data at the American Academy of Dermatology meeting, showing ZORYVE (roflumilast) cream 0.05% was well tolerated and improved skin clearance in infants aged 3 to 24 months with mild to moderate atopic dermatitis. This positive pediatric dataset underpins Arcutis’s plan to file a supplemental FDA application in the second quarter of 2026, potentially broadening ZORYVE’s reach into very young patients. Next,...

Why Allegiant Travel Is On Investor Radar Today Allegiant Travel (ALGT) has drawn fresh attention after recent share price moves, with the stock closing at US$90.35 and showing varied performance over the past week, month and past 3 months. See our latest analysis for Allegiant Travel. Although the share price is slightly lower on the day, the recent 17.26% 1 month share price return comes on top of a 120.9% 1 year total shareholder return. This suggests momentum has picked up after a much...

If you are wondering whether Berkshire Hathaway is attractively priced at around US$706,750.01 per share, the key is understanding what that tag really represents in terms of underlying value. The stock has seen a 1.4% decline over the last 7 days and a 1.9% decline over the last 30 days, alongside a 5.0% decline year to date and a 9.4% decline over the last year, set against 42.7% and 71.8% returns over the past 3 and 5 years respectively. Recent headlines have focused on Berkshire...

Grindr (GRND) recently launched Out in the Open, a Grindr for Equality content series on chemsex, addiction, and mental health, integrating support resources from partners like You Are Loved and Switchboard directly into its app. See our latest analysis for Grindr. Alongside this new Grindr for Equality initiative, the stock has shown gaining momentum, with a 10.87% 90 day share price return and a 109.40% three year total shareholder return, despite a 30.78% total shareholder return decline...

Wondering whether QXO at around US$24.22 is offering value or asking too much of future expectations? This breakdown is designed to help you weigh that up calmly and clearly. The stock has shown sharp moves recently, with returns of 9.1% over 7 days, 29.9% over 30 days, 22.8% year to date, 90.4% over 1 year, 18.4% over 3 years, and a 38.4% decline over 5 years. These mixed returns give important context for thinking about what investors are currently pricing in and how sentiment toward QXO...

In April 2026, ANI Pharmaceuticals launched three U.S. generics, Carbamazepine Extended-Release Capsules, Pimozide Tablets, and Isosorbide Mononitrate Tablets, targeting reference drugs Carbatrol, Orap, and Monoket, in markets with combined annual sales of about US$68.10 million based on IQVIA data. Away from generics, the publication of Phase 4 NEW DAY trial results for ILUVIEN in Ophthalmology underscores ANI’s focus on evidence generation and its efforts to support adoption of its retina...

Delta Air Lines (NYSE:DAL) is trimming select summer routes as jet fuel prices remain elevated due to ongoing geopolitical conflict. The carrier is also removing a previously stated 2030 target for sustainable aviation fuel from its climate roadmap. Delta is reframing its longer term net zero objective, updating how it presents emissions and decarbonization plans to investors. Delta Air Lines, one of the largest global network carriers, is adjusting both its schedule and climate roadmap at...

Recent performance snapshot Adobe (ADBE) has been on many investors’ radars after a mixed run in the stock, with the share price around $248.63 and returns over the past year and past 3 years both in negative territory. See our latest analysis for Adobe. After a weak patch over recent quarters, Adobe’s 7 day share price return of 3.55% and 1 day gain of 1.71% hint at stabilising momentum, even as the 1 year total shareholder return remains 27.56% lower. If Adobe’s recent moves have you...